Jazz Pharmaceuticals (JAZZ) EVP awarded 9,782 restricted stock units in Form 4

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc executive Samantha Pearce, EVP and Chief Commercial Officer, received an equity award tied to the company’s ordinary shares. She acquired 9,782 restricted stock units, with no cash paid per share, increasing her directly held stake to 52,775 ordinary shares after the transaction.

Each restricted stock unit represents a right to receive one ordinary share if it vests under the company’s 2011 Equity Incentive Plan. The award vests in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary of that date and the remainder vesting annually over the following three years.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pearce Samantha

Role EVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	9,782	$0.00	--

Holdings After Transaction: Ordinary Shares — 52,775 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pearce Samantha

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/26/2026		A(1)		9,782	A	$0.0	52,775	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

	By: /s/Paz Dizon, as attorney in fact For: Samantha J. Pearce	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Samantha Pearce report in this Jazz Pharmaceuticals (JAZZ) Form 4 filing?

Samantha Pearce reported receiving 9,782 restricted stock units linked to Jazz Pharmaceuticals’ ordinary shares. These are equity awards granted at no cash cost per share and increase her directly held stake to 52,775 ordinary shares after this grant.

How many Jazz Pharmaceuticals (JAZZ) shares does Samantha Pearce hold after this transaction?

After this transaction, Samantha Pearce beneficially owns 52,775 ordinary shares of Jazz Pharmaceuticals. This figure includes the impact of the 9,782 restricted stock units granted in the award reported in this Form 4 filing for the executive.

What are the terms of the 9,782 restricted stock units granted by Jazz Pharmaceuticals (JAZZ)?

The 9,782 restricted stock units were granted under Jazz Pharmaceuticals’ 2011 Equity Incentive Plan. Each unit converts into one ordinary share upon vesting, following a four-year schedule based on equal annual installments measured from March 5, 2026.

When do Samantha Pearce’s new Jazz Pharmaceuticals (JAZZ) restricted stock units vest?

The restricted stock units vest over four years starting from a vesting commencement date of March 5, 2026. One-quarter vests on the first anniversary, with the remaining units vesting in equal annual installments over the subsequent three years.

Did Samantha Pearce pay cash for the Jazz Pharmaceuticals (JAZZ) shares in this Form 4?

No cash was paid for the shares associated with this award, as indicated by the transaction price of 0.0000 per share. The filing reflects a grant of restricted stock units rather than an open-market purchase of Jazz Pharmaceuticals ordinary shares.

Under which plan were the Jazz Pharmaceuticals (JAZZ) restricted stock units granted to Samantha Pearce?

The restricted stock units were granted pursuant to Jazz Pharmaceuticals’ 2011 Equity Incentive Plan. This plan provides for equity-based awards, and each restricted stock unit represents a contingent right to receive one ordinary share upon meeting the vesting conditions.